SNSE - Rasio utang marang kapitalisasi buku Sensei Biotherapeutics Inc

Logo korporat perusahaan senseibio.com (SNSE)

The dynamics of the debt-to-capitalization ratio on the balance sheet are based on Sensei Biotherapeutics revenues from grants and personalized oncology research. The development of targeted antibodies to block tumors and a plan to accelerate trials of drugs against solid tumors ensure increased stability. The value of 0.09 shows the current level of this metric, determining the risk of bankruptcy or the pace of business expansion.

SNSE Sensei Biotherapeutics Inc: Rasio utang marang kapitalisasi buku ing interval 04.07.2022 - 16.06.2026
Produk dadi Sensei Biotherapeutics Inc

Retaining leading immuno-oncologists through stock option programs minimizes the need for Sensei Biotherapeutics (SNSE) to secure costly loans. This indicator measures the share of total borrowings relative to equity, determining the degree of financial leverage. It is critical for investors to find a balance between default risk and the efficiency of using borrowed funds for growth. Analyzing the ratio of the company's financial debt to balance sheet equity allows for an assessment of the funding structure's stability. This chart confirms the issuer's solvency.

Pesaing Sensei Biotherapeutics

ImmunityBio, Inc. - Utang-utang marang kapitalisasi buku|immunocore.com - Utang marang nilai buku|JANX (Janux Therapeutics, Inc.) - Rasio utang marang kapitalisasi buku|RCUS: Utang-utang marang nilai buku|Zymeworks Corp (ZYME) - Rasio utang marang kapitalisasi buku|TNGX (Tango Therapeutics Corp) - Rasio utang marang kapitalisasi buku|Rasio utang marang kapitalisasi buku IOVA (Iovance Biotherapeutics)|Utang-utang marang nilai buku immatics.com|XNCR: Utang-utang marang kapitalisasi buku|Utang marang aset resik Compass Therapeutics Inc CMPX|REPL: Utang marang nilai buku|LYEL - Utang-utang marang nilai buku|Utang marang nilai buku Innate Pharma S.A. (IPHA)|PYXS - Rasio utang marang aset resik|cgen.com - Utang-utang marang kapitalisasi buku|IOBT (IO Biotech Inc) - Utang-utang marang aset resik|Rasio utang marang kapitalisasi buku STRO|Utang marang nilai buku INKT|Rasio utang marang kapitalisasi buku HOWL (Werewolf Therapeutics)|Utang marang nilai buku immixbio.com IMMX|Utang marang nilai buku ALXO (ALX Oncology Holdings)|cuebiopharma.com - Utang-utang marang kapitalisasi buku|PDS Biotechnology Corp (PDSB) - Rasio utang marang kapitalisasi buku|SONN: Rasio utang marang nilai buku|Rasio utang marang kapitalisasi buku MAIA|Utang-utang marang nilai buku liminatuspharma.com|LAVA Therapeutics NV - Utang marang nilai buku|Utang marang aset resik NextCure Inc (NXTC)|Utang marang nilai buku Leap Therapeutics, Inc.|Utang marang modal buku intensitytherapeutics.com (INTS)|Utang-utang marang kapitalisasi buku Theriva Biologics, Inc.|Rasio utang marang aset resik Gritstone bio Inc. GRTS|KA (Kineta) - Utang-utang marang kapitalisasi buku|NEXI: Utang-utang marang nilai buku|Rasio utang marang kapitalisasi buku turnstonebio.com TSBX|Vaccinex Inc (VCNX) - Rasio utang marang aset resik|HARP (Harpoon Therapeutics) - Utang-utang marang kapitalisasi buku